Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers

Journal of Drug Targeting

Volumn 24, Issue 4, 2016, Pages 328-339

  Cho, S ^a,c   Dong, S ^a   Parent, K N ^b   Chen, M ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Michigan State University   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic T lymphocyte (CTL) vaccine; immune tolerant elastin like polypeptide; inverse phase transition; non canonical elastin like polypeptide motifs; reversible; thermally induced; vaccine carrier

Indexed keywords

CYTOTOXIC T LYMPHOCYTE VACCINE; ELASTIN LIKE POLYPEPTIDE; PEPTIDE VACCINE; POLYPEPTIDE; UNCLASSIFIED DRUG; VACCINE; DRUG CARRIER; ELASTIN; IMMUNOGLOBULIN G; NANOPARTICLE; PEPTIDE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ARTICLE; ASSAY; CONTROLLED STUDY; DENDRITIC CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; TURBIDITY; TURBIDITY ASSAY; AMINO ACID SEQUENCE; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; PROTEIN MOTIF; SPLEEN; TRANSITION TEMPERATURE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; DRUG CARRIERS; DRUG DESIGN; ELASTIN; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; PHASE TRANSITION; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSITION TEMPERATURE; VACCINES, SYNTHETIC;

EID: 84956573779     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1077847     Document Type: Article

References (67)

1. Robinson HL, Amara RR. T cell vaccines for microbial infections. Nat Med 2005;11:s25-32.
2. Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011;334:475-80.
3. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27-44.
4. Schumacher R, Amacker M, Neuhaus D, et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine 2005;23: 5572-82.
5. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. WIREs Nanomed Nanobiotechnol 2011;3:174-96.
6. Goldberg MS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 2015;161:201-4.
7. Sahdev P, Ochyl L, Moon J. Biomaterials for nanoparticle vaccine delivery systems. Pharm Res 2014;31:2563-82.
8. Dreher MR, Simnick AJ, Fischer K, et al. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. J Am Chem Soc 2008;130:687-94.
9. Hassouneh W, Fischer K, MacEwan SR, et al. Unexpected multivalent display of proteins by temperature triggered selfassembly of elastin-like polypeptide block copolymers. Biomacromolecules 2012;13:1598-605.
10. Scheller J, Leps M, Conrad U. Forcing single-chain variable fragment production in tobacco seeds by fusion to elastin-like polypeptides. Plant Biotechnol J 2006;4:243-9.
11. Alexander J, Oseroff C, Dahlberg C, et al. A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol 2002;168:6189-98.
12. Livingston BD, Newman M, Crimi C, et al. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001;19:4652-60.
13. Thomson SA, Khanna R, Gardner J, et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 1995;92:5845-9.
14. Hassouneh W, Christensen T, Chilkoti A. Elastin-like polypeptides as a purification tag for recombinant proteins. Curr Protoc Protein Sci 2010; Chapter 6: Unit 6 11.
15. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 2001;290:350-60.
16. Ruedl C, Schwarz K, Jegerlehner A, et al. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 2005;79:717-24.
17. Liu XS, Xu Y, Hardy L, et al. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 2003;171:4765-72.
18. Urry DW, Parker TM, Reid MC, Gowda DC. Biocompatibility of the bioelastic materials, poly(GVGVP) and its g-irradiation crosslinked matrix: summary of generic biological test results. J Bioactive Compatible Polym 1991;6:263-82.
19. Urry DW, Pattanaik A, Accavitti MA, et al. Transductional elastic and plastic protein-based polymers as potential medical devices. In: Domb AJ, Kost J, Wiseman DM, eds. Handbook of biodegradable polymers. Amsterdam, The Netherlands: CRC Press; 1998.
20. Christiansen M, Matson M, Brazg RL, et al. Weekly subcutaneous doses of Glymera (PB1023) a novel GLP-1 analogue reduce glucose exposure dose-dependently. American Diabetes Association 72nd Scientific Sessions 2012.
21. Cappello J. Genetically engineered protein polymers. In: Domb AJ, Kost J, Wiseman DM, eds. Handbook of biodegradable polymers. Amsterdam: Harwood Academic Publishers; 1997:387-416.
22. Nouri F, Wang X, Chen X, Hatefi A. Reducing the visibility of the vector/DNA nanocomplexes to the immune system by elastin-Like peptides. Pharm Res 2015;32:3018-28.
23. Garcia-Arevalo C, Bermejo-Martin JF, Rico L, et al. Immunomodulatory nanoparticles from elastin-like recombinamers: single-molecules for tuberculosis vaccine development. Mol Pharm 2013;10:586-97.
24. Moreland LW, McCabe DP, Caldwell JR, et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol 2000;27:601-9.
25. Rau R, Sander O, van Riel P, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. J Rheumatol 2003;30:680-90.
26. Urry DW. Free energy transduction in polypeptides and proteins based on inverse temperature transitions. Prog Biophys Mol Biol 1992;57:23-57.
27. MacEwan SR, Chilkoti A. Elastin-like polypeptides: biomedical applications of tunable biopolymers. Pept Sci 2010;94:60-77.
28. McDaniel JR, Mackay JA, Quiroz FG, Chilkoti A. Recursive directional ligation by plasmid reconstruction allows rapid and seamless cloning of oligomeric genes. Biomacromolecules 2010; 11:944-52.
29. Rock KL, Fleischacker C, Gamble S. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. J Immunol 1993;150:1244-52.
30. Zhao P, Dong S, Bhattacharyya J, Chen M. iTEP nanoparticle delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol Pharm 2014;11:2703-12.
31. Lee C, Levin A, Branton D. Copper staining: a five-minute protein stain for sodium dodecyl sulfate-polyacrylamide gels. Anal Biochem 1987;166:308-12.
32. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998;221:35-41.
33. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997;158:2723-30.
34. Karttunen J, Sanderson S, Shastri N. Detection of rare antigenpresenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci 1992;89:6020-4.
35. Bernard A, Coitot S, Bremont A, Bernard G. T and B cell cooperation: a dance of life and death. Transplantation 2005;79:S8-11.
36. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993;11:331-60.
37. Murphy K. The humoral immune response in Janeway's immunobiology. London and New York: Garland Science; 2012:387-428.
38. Van Regenmortel MH. Molecular disection of protein antigens. In: Van Regenmortel MH, ed. Structure of antigens. Boca Raton (FL): CRC Press;1992:1-28.
39. Sela M. Antigenicity: some molecular aspects. Science 1969;166: 1365-74.
40. Murphy K. The development and survival of lymphocytes. in Janeway's Immunobiology. London and New York: Garland Science; 2012:275-333.
41. Liu W, Peng Z, Liu Z, et al. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004;23:366-71.
42. Kovacs-Nolan J, Mine Y. Tandem copies of a human rotavirus VP8 epitope can induce specific neutralizing antibodies in BALB/c mice. Biochim Biophys Acta 2006;1760:1884-93.
43. Partidos C, Stanley C, Steward M. The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides. Eur J Immunol 1992;22:2675-80.
44. Onda M, Beers R, Xiang L, et al. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008;105:11311-16.
45. Onda M, Nagata S, Fitz Gerald DJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822-34.
46. Smejkal GB. The coomassie chronicles: past, present and future perspectives in polyacrylamide gel staining. Expert Rev Proteomics 2004;1:381-7.
47. Creighton TE. Proteins: structures and molecular properties. New York: W.H. Freeman Company; 1993.
48. Urry DW, Luan CH, Parker TM, et al. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J Am Chem Soc 1991;113:4346-8.
49. Meyer DE, Chilkoti A. Quantification of the effects of chain length and concentration on the thermal behavior of elastin-like polypeptides. Biomacromolecules 2004;5:846-1.
50. Jefferis R. Aggregation, immune complexes and immunogenicity. MABS 2011;3:503-4.
51. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8:E501-7.
52. Zhou L, Hoofring S, Wu Y, et al. Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J 2013;15:30-40.
53. Kontos S, Hubbell JA. Drug development: longer-lived proteins. Chem Soc Rev 2012;41:2686-95.
54. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007;28:482-90.
55. U.S. Department of Health and Human Services Food and Drug Administration, Guidance for industry immunogenicity assessment for therapeutic protein products. Silver Spring (MD): U.S. Department of Health and Human Services Food and Drug Administration; 2013.
56. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006;24:274-80.
57. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol 1997;15:235-70.
58. Feldmann M, Basten A. The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med 1971;134:103-19.
59. Urry DW. Physical chemistry of biological free energy transductioin as demonstrated by elastic protein-based polymers. J Phys Chem B 1997;101:11007-28.
60. Chilkoti A, Dreher MR, Meyer DE, Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev 2002;54:613-30.
61. Liu W, MacKay JA, Dreher MR, et al. Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. J Control Release 2010;144: 2-9.
62. MacKay JA, Chen M, McDaniel JR, et al. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 2009;8: 993-9.
63. Shi P, Aluri S, Lin YA, et al. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo. J Control Release 2013;171:330-8.
64. Bidwell 3rd GL, Perkins E, Hughes J, et al. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS One 2013;8: e55104.
65. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today 2013;18:807-17.
66. Le DH, Hanamura R, Pham DH, et al. Self-assembly of elastinmimetic double hydrophobic polypeptides. Biomacromolecules 2013;14:1028-34.
67. Benitez PL, Sweet JA, Fink H, et al. Sequence-specific crosslinking of electrospun, elastin-like protein preserves bioactivity and native-like mechanics. Adv Healthc Mater 2013;2: 114-18.